Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Minghua Shan

Showing results (1-10 of 10) with videos related to

Pageof 1
Sort By:
Pharmaceutical Statistics|December 18, 2020
A confidence function-based posterior probability design for phase II cancer trialsMinghua Shan
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 24, 2010
Biomarkers predicting outcome in patients with advanced renal cell carcinoma: Results from sorafenib phase III Treatment Approaches in Renal Cancer Global Evaluation TrialCarol Peña, Chetan Lathia, Minghua Shan, et al.
Molecular Vision|September 24, 2005
Novel mutations in the CYP4V2 gene associated with Bietti crystalline corneoretinal dystrophyMinghua Shan, Bing Dong, Xueqin Zhao, et al.
Trials|July 24, 2013
A phase 3 tRial comparing capecitabinE in combination with SorafenIb or pLacebo for treatment of locally advanced or metastatIc HER2-Negative breast CancEr (the RESILIENCE study): study protocol for a randomized controlled trialJosé Baselga, Frederico Costa, Henry Gomez, et al.
Gynecologic Oncology|April 18, 2013
A randomized phase II trial of maintenance therapy with Sorafenib in front-line ovarian carcinomaThomas J Herzog, Giovanni Scambia, Byoung-Gie Kim, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 20, 2009
Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trialBernard Escudier, Tim Eisen, Walter M Stadler, et al.
The New England Journal of Medicine|January 12, 2007
Sorafenib in advanced clear-cell renal-cell carcinomaBernard Escudier, Tim Eisen, Walter M Stadler, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 22, 2024
Improving Collection and Analysis of Overall Survival DataLisa R Rodriguez, Nicole J Gormley, Ruixiao Lu, et al.
The Lancet. Oncology|May 20, 2014
Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: results from a phase 3, double-blind, randomised trialOliver Sartor, Robert Coleman, Sten Nilsson, et al.
The New England Journal of Medicine|July 25, 2008
Sorafenib in advanced hepatocellular carcinomaJosep M Llovet, Sergio Ricci, Vincenzo Mazzaferro, et al.
Pageof 1

Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
Pharmaceutical Statistics|December 18, 2020
A confidence function-based posterior probability design for phase II cancer trialsMinghua Shan
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 24, 2010
Biomarkers predicting outcome in patients with advanced renal cell carcinoma: Results from sorafenib phase III Treatment Approaches in Renal Cancer Global Evaluation TrialCarol Peña, Chetan Lathia, Minghua Shan, et al.
Molecular Vision|September 24, 2005
Novel mutations in the CYP4V2 gene associated with Bietti crystalline corneoretinal dystrophyMinghua Shan, Bing Dong, Xueqin Zhao, et al.
Trials|July 24, 2013
A phase 3 tRial comparing capecitabinE in combination with SorafenIb or pLacebo for treatment of locally advanced or metastatIc HER2-Negative breast CancEr (the RESILIENCE study): study protocol for a randomized controlled trialJosé Baselga, Frederico Costa, Henry Gomez, et al.
Gynecologic Oncology|April 18, 2013
A randomized phase II trial of maintenance therapy with Sorafenib in front-line ovarian carcinomaThomas J Herzog, Giovanni Scambia, Byoung-Gie Kim, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 20, 2009
Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trialBernard Escudier, Tim Eisen, Walter M Stadler, et al.
The New England Journal of Medicine|January 12, 2007
Sorafenib in advanced clear-cell renal-cell carcinomaBernard Escudier, Tim Eisen, Walter M Stadler, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 22, 2024
Improving Collection and Analysis of Overall Survival DataLisa R Rodriguez, Nicole J Gormley, Ruixiao Lu, et al.
The Lancet. Oncology|May 20, 2014
Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: results from a phase 3, double-blind, randomised trialOliver Sartor, Robert Coleman, Sten Nilsson, et al.
The New England Journal of Medicine|July 25, 2008
Sorafenib in advanced hepatocellular carcinomaJosep M Llovet, Sergio Ricci, Vincenzo Mazzaferro, et al.
Pageof 1